Rapport Therapeutics, Inc. - Form 4 Filing

This filing details transactions by Yeleswaram Krishnaswamy, Chief Development Officer of Rapport Therapeutics, Inc. On August 24, 2026, 13,160 shares of Common Stock were sold at a weighted average price of $49.9983, under a Rule 10b5-1 trading plan. Following this transaction, 232,862 shares remained. On August 25, 2026, two transactions occurred: 20,799 shares were sold at a weighted average price of $50.3111, leaving 212,063 shares, and 16,201 shares were sold at a weighted average price of $51.0576, resulting in 195,862 shares. These sales were also executed under the pre-established trading plan. The weighted average prices reflect sales across a range of prices as detailed in the footnotes.